SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Abamectin Liquid Formulation

Version 4.5 Revision Date: 27.08.2021 SDS Number: 1212762-00014 Date of last issue: 26.04.2021 Date of first issue: 10.01.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Ivermectin / Abamectin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet
Company: MSD
Kilsheolan
Clonmel Tipperary, IE

Telephone: 353-51-601000
E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Acute toxicity, Category 4 H302: Harmful if swallowed.
Acute toxicity, Category 4 H332: Harmful if inhaled.
Skin irritation, Category 2 H315: Causes skin irritation.
Eye irritation, Category 2 H319: Causes serious eye irritation.
Reproductive toxicity, Category 1B H360D: May damage the unborn child.
Specific target organ toxicity - single exposure, Category 2 H371: May cause damage to organs.
Specific target organ toxicity - single exposure, Category 3 H335: May cause respiratory irritation.
Specific target organ toxicity - repeated exposure, Category 2 H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1 H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1 H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
SAFETY DATA SHEET  
according to Regulation (EC) No. 1907/2006

Ivermectin / Abamectin Liquid Formulation

Version 4.5  
Revision Date: 27.08.2021  
SDS Number: 1212762-00014  
Date of last issue: 26.04.2021  
Date of first issue: 10.01.2017

Hazard pictograms : 

Signal word : Danger

Hazard statements : H302 + H332  Harmful if swallowed or if inhaled.  
H315  Causes skin irritation.  
H319  Causes serious eye irritation.  
H335  May cause respiratory irritation.  
H360D  May damage the unborn child.  
H371  May cause damage to organs.  
H373  May cause damage to organs through prolonged or repeated exposure.  
H410  Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:  
P201  Obtain special instructions before use.  
P273  Avoid release to the environment.  
P280  Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:  
P304 + P340 + P312  IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.  
P308 + P311  IF exposed or concerned: Call a POISON CENTER/ doctor.  
P391  Collect spillage.

Hazardous components which must be listed on the label:  
N-Methyl-2-pyrrolidone  
Ivermectin  
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

Additional Labelling  
Restricted to professional users.

2.3 Other hazards  
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
### SECTION 3: Composition/information on ingredients

#### 3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N-Methyl-2-pyrrolidone</td>
<td>872-50-4  212-828-1  606-021-00-7</td>
<td>Skin Irrit. 2; H315  Eye Irrit. 2; H319  Repr. 1B; H360D  STOT SE 3; H335</td>
<td>&gt;= 20 - &lt; 30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>specific concentration limit  STOT SE 3; H335 &gt;= 10 %</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ivermectin</td>
<td>70288-86-7  274-536-0</td>
<td>Acute Tox. 2; H300  Acute Tox. 3; H311  STOT SE 1; H370 (Central nervous system)  STOT RE 1; H372 (Central nervous system)  Aquatic Acute 1; H400  Aquatic Chronic 1; H410</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
<tr>
<td></td>
<td>abamectin (combination of avermectin B1a and avermectin B1b) (ISO)</td>
<td>71751-41-2  606-143-00-0</td>
<td>Acute Tox. 2; H300  Acute Tox. 1; H330  Acute Tox. 3; H311  Repr. 2; H361fd  STOT RE 1; H372 (Central nervous system)  Aquatic Acute 1; H400  Aquatic Chronic 1; H410</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M-Factor (Acute aquatic toxicity): 10,000  M-Factor (Chronic aquatic toxicity): 10,000</td>
<td></td>
</tr>
</tbody>
</table>
**SECTION 4: First aid measures**

**4.1 Description of first aid measures**

**General advice**: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders**: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**If inhaled**: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

**In case of skin contact**: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

**In case of eye contact**: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

**If swallowed**: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
4.2 Most important symptoms and effects, both acute and delayed

Risks: Harmful if swallowed or if inhaled. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
6.2 Environmental precautions
Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Abamectin Liquid Formulation

Version 4.5  Revision Date: 27.08.2021  SDS Number: 1212762-00014  Date of last issue: 26.04.2021  Date of first issue: 10.01.2017

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
- Strong oxidizing agents
- Organic peroxides
- Explosives
- Gases

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Occupational Exposure Limits</th>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N-Methyl-2-pyrrolidone</td>
<td>872-50-4</td>
<td>TWA</td>
<td>10 ppm 40 mg/m3</td>
<td>2009/161/EU</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Further information: Identifies the possibility of significant uptake through the skin, Indicative</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>STEL</td>
<td>20 ppm 80 mg/m3</td>
<td>2009/161/EU</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Further information: Identifies the possibility of significant uptake through the skin, Indicative</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>OELV - 8 hrs (TWA)</td>
<td>10 ppm 40 mg/m3</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>OELV - 15 min (STEL)</td>
<td>20 ppm 80 mg/m3</td>
<td>IE OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Further information: Skin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>0.5 mg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td>abamectin (combination of avermectin B1a and avermectin B1b) (ISO)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>15 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>150 µg/100 cm²</td>
</tr>
<tr>
<td></td>
<td>(dl)-a-Tocopheryl</td>
<td>7695-91-2</td>
<td>TWA</td>
<td>5000 ug/m3 (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Methyl-2-pyrrolidone</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>14.4 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>40 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>4.8 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>3.6 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>2.4 mg/kg bw/day</td>
</tr>
<tr>
<td>(dl)-a-Tocopheryl acetate</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>73.5 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>416.6 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>21.7 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>250 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>12.5 mg/kg bw/day</td>
</tr>
</tbody>
</table>

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Methyl-2-pyrrolidone</td>
<td>Fresh water</td>
<td>0.25 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>5 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.025 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>10 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>1.09 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>1.09 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.07 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>(dl)-a-Tocopheryl acetate</td>
<td>Fresh water</td>
<td>0.27 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.027 mg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>0.27 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>100 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>212000 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>21200 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>74800 mg/kg</td>
</tr>
</tbody>
</table>
8.2 Exposure controls

**Engineering measures**
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

**Personal protective equipment**

- **Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

- **Hand protection**: Chemical-resistant gloves.
  Remarks: Consider double gloving.

- **Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387
  Filter type: Combined particulates and organic vapour type (A-P)

**SECTION 9: Physical and chemical properties**

**9.1 Information on basic physical and chemical properties**

- **Physical state**: liquid
- **Colour**: light yellow
- **Odour**: characteristic
- **Odour Threshold**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Flammability (liquids)**: Not applicable
- **Upper explosion limit / Upper flammability limit**: No data available
Ivermectin / Abamectin Liquid Formulation

Lower explosion limit / Lower flammability limit: No data available
Flash point: > 100 °C
Auto-ignition temperature: No data available
Decomposition temperature: No data available
pH: Not applicable
Viscosity
  Viscosity, kinematic: No data available
Solubility(ies)
  Water solubility: insoluble
Partition coefficient: n-octanol/water: Not applicable
Vapour pressure: No data available
Relative density: No data available
Density: 0.91 - 1.00 mg/l
Relative vapour density: No data available
Particle characteristics
  Particle size: Not applicable

9.2 Other information
Explosives: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Evaporation rate: No data available
Molecular weight: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Harmful if swallowed or if inhaled.

Product:
Acute oral toxicity : Acute toxicity estimate: 1,031 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.84 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

N-Methyl-2-pyrrolidone:
Acute oral toxicity : LD50 (Rat): 4,150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

Ivermectin:
Acute oral toxicity : LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

_abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity: LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LD50 (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity: LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

(dl)-a-Tocopheryl acetate:

Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity: LD50 (Rat): > 3,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

_Skin corrosion/irritation_
Causes skin irritation.

_Components:

N-Methyl-2-pyrrolidone:
Result: Skin irritation

Ivermectin:
Species: Rabbit
Result: No skin irritation

_abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species: Rabbit
Result: No skin irritation

(dl)-a-Tocopheryl acetate:
Ivermectin / Abamectin Liquid Formulation

Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

**Serious eye damage/eye irritation**
Causes serious eye irritation.

**Components:**

**N-Methyl-2-pyrrolidone:**
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days

**Ivermectin:**
Species: Rabbit
Result: Mild eye irritation

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
Species: Rabbit
Result: Mild eye irritation

**(dl)-a-Tocopheryl acetate:**
Species: Rabbit
Method: OECD Test Guideline 405
Result: No eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**N-Methyl-2-pyrrolidone:**
Test Type: Local lymph node assay (LLNA)
Exposure routes: Skin contact
Species: Mouse
Method: OECD Test Guideline 429
Result: negative
Remarks: Based on data from similar materials

**Ivermectin:**
Exposure routes: Dermal
Species: Humans
Result: Does not cause skin sensitisation.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
## Ivermectin / Abamectin Liquid Formulation

### Test Type:
- **Maximisation Test**

### Exposure routes:
- Skin contact

### Result:
- Not a skin sensitizer.

### (dl)-a-Tocopheryl acetate:
- **Draize Test**
- **Species**: Humans
- **Result**: negative

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### N-Methyl-2-pyrrolidone:
- **Genotoxicity in vitro**
  - **Test Type**: Bacterial reverse mutation assay (AMES)
  - **Method**: OECD Test Guideline 471
  - **Result**: negative

  - **Test Type**: In vitro mammalian cell gene mutation test
  - **Method**: OECD Test Guideline 476
  - **Result**: negative

  - **Test Type**: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - **Result**: negative

- **Genotoxicity in vivo**
  - **Test Type**: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - **Species**: Mouse
  - **Application Route**: Ingestion
  - **Method**: OECD Test Guideline 474
  - **Result**: negative

  - **Test Type**: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  - **Species**: Hamster
  - **Application Route**: Ingestion
  - **Method**: OECD Test Guideline 475
  - **Result**: negative

#### Ivermectin:
- **Genotoxicity in vitro**
  - **Test Type**: Bacterial reverse mutation assay (AMES)
  - **Result**: negative

  - **Test Type**: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
    - **Test system**: human diploid fibroblasts
    - **Result**: negative

  - **Test Type**: Mouse Lymphoma
Ivermectin / Abamectin Liquid Formulation

Result: negative

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo:
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

**(dl)-a-Tocopheryl acetate:**

Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

**Carcinogenicity**
Not classified based on available information.

**Components:**

**N-Methyl-2-pyrrolidone:**
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Species: Rat
Application Route: Inhalation (vapour)
Exposure time: 2 Years
Result: negative
ivermectin:

Species: Rat
Application Route: Oral
NOAEL: 1.5 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

(dl)-a-Tocopheryl acetate:

Species: Rat
Application Route: Ingestion
Exposure time: 104 weeks
Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

N-Methyl-2-pyrrolidone:

Effects on fertility:
Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative

Effects on foetal development:
Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapour)
Result: positive
Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: positive

Reproductive toxicity - Assessment  
: Clear evidence of adverse effects on development, based on animal experiments.

Ivermectin:

Effects on fertility  
: Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0.6 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on foetal development  
: Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight  
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility  
: Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight  
Result: Fetotoxicity
### Effects on foetal development

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>General Toxicity Maternal</th>
<th>Developmental Toxicity</th>
<th>Result</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embryo-foetal development</td>
<td>Mouse</td>
<td>Oral</td>
<td>NOAEL: 0.05 mg/kg body weight</td>
<td>NOAEL: 0.2 mg/kg body weight</td>
<td>Cleft palate</td>
<td>Adverse developmental effects were observed</td>
</tr>
<tr>
<td>Embryo-foetal development</td>
<td>Rabbit</td>
<td>Oral</td>
<td>LOAEL: 2 mg/kg body weight</td>
<td></td>
<td>Cleft palate, Teratogenic effects, Reduced embryonic survival</td>
<td>Adverse developmental effects were observed</td>
</tr>
<tr>
<td>Development</td>
<td>Rat</td>
<td>Oral</td>
<td>LOAEL: 1.6 mg/kg body weight</td>
<td></td>
<td>Teratogenic effects</td>
<td></td>
</tr>
</tbody>
</table>

### Reproductive toxicity - Assessment

- Some evidence of adverse effects on sexual function and fertility, based on animal experiments.
- Some evidence of adverse effects on development, based on animal experiments.

### (dl)-a-Tocopheryl acetate

- **Effects on fertility**
  - Test Type: Reproduction/Developmental toxicity screening test
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative

- **Effects on foetal development**
  - Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Ingestion
  - Result: negative

### STOT - single exposure

- May cause respiratory irritation.
- May cause damage to organs.

### Components

#### N-Methyl-2-pyrrolidone

- **Assessment**: May cause respiratory irritation.

#### Ivermectin

- **Target Organs**: Central nervous system
- **Assessment**: Causes damage to organs.
Ivermectin / Abamectin Liquid Formulation

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

**Components:**

**Ivermectin:**
- **Target Organs**: Central nervous system
- **Assessment**: Causes damage to organs through prolonged or repeated exposure.

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
- **Exposure routes**: Ingestion
- **Target Organs**: Central nervous system
- **Assessment**: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**N-Methyl-2-pyrroldione:**
- **Species**: Rat, male
- **NOAEL**: 169 mg/kg
- **LOAEL**: 433 mg/kg
- **Application Route**: Ingestion
- **Exposure time**: 90 Days
- **Method**: OECD Test Guideline 408

Species: Rat
- **NOAEL**: 0.5 mg/l
- **LOAEL**: 1 mg/l
- **Application Route**: inhalation (dust/mist/fume)
- **Exposure time**: 96 Days
- **Method**: OECD Test Guideline 413

Species: Rabbit
- **NOAEL**: 826 mg/kg
- **LOAEL**: 1,653 mg/kg
- **Application Route**: Skin contact
- **Exposure time**: 20 Days

**Ivermectin:**
- **Species**: Dog
- **NOAEL**: 0.5 mg/kg
- **LOAEL**: 1 mg/kg
- **Application Route**: Oral
- **Exposure time**: 14 Weeks
- **Target Organs**: Central nervous system
- **Symptoms**: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species: Monkey
- **NOAEL**: 1.2 mg/kg
Ivermectin / Abamectin Liquid Formulation

Application Route: Oral
Exposure time: 2 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 0.4 mg/kg
LOAEL: 0.8 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: spleen, Bone marrow, Kidney

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species: Rat
NOAEL: 1.5 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia

Species: Mouse
NOAEL: 4.0 mg/kg
Application Route: Oral
Exposure time: 24 Months
Target Organs: Central nervous system
Symptoms: Tremors, ataxia

Species: Dog
NOAEL: 0.25 mg/kg
LOAEL: 0.5 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Target Organs: Central nervous system
Symptoms: Tremors, weight loss
Remarks: mortality observed

Species: Monkey
NOAEL: 1.0 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system

(dl)-a-Tocopheryl acetate:

Species: Rat
NOAEL: 500 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Aspiration toxicity
Not classified based on available information.
11.2 Information on other hazards

Endocrine disrupting properties

**Product:**
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

**Components:**

**N-Methyl-2-pyrrolidone:**
Skin contact: Symptoms: Skin irritation

**Ivermectin:**
Skin contact: Remarks: Can be absorbed through skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
Ingestion: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12: Ecological information

12.1 Toxicity

**Components:**

**N-Methyl-2-pyrrolidone:**
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l Exposure time: 24 h Method: DIN 38412

Toxicity to algae/aquatic plants: ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l Exposure time: 72 h

Toxicity to microorganisms: EC50 : > 600 mg/l Exposure time: 30 min Method: ISO 8192

Toxicity to daphnia and other aquatic invertebrates (Chron-
### Ivermectin / Abamectin Liquid Formulation

**Species:** Daphnia magna (Water flea)
**Method:** OECD Test Guideline 211

#### Ivermectin:

<table>
<thead>
<tr>
<th>Category</th>
<th>Species/Method</th>
<th>LC50 (mg/l)</th>
<th>Exposure time (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity to fish</td>
<td>Oncorhynchus mykiss (rainbow trout)</td>
<td>0.003</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Lepomis macrochirus (Bluegill sunfish)</td>
<td>0.0048</td>
<td>96</td>
</tr>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates</td>
<td>Daphnia magna (Water flea)</td>
<td>0.000025</td>
<td>48</td>
</tr>
<tr>
<td>Toxicity to algae/aquatic plants</td>
<td>Pseudokirchneriella subcapitata (green algae)</td>
<td>&gt; 9.1</td>
<td>72</td>
</tr>
<tr>
<td>M-Factor (Acute aquatic toxicity)</td>
<td></td>
<td>10,000</td>
<td></td>
</tr>
<tr>
<td>M-Factor (Chronic aquatic toxicity)</td>
<td></td>
<td>10,000</td>
<td></td>
</tr>
</tbody>
</table>

#### Abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

<table>
<thead>
<tr>
<th>Category</th>
<th>Species/Method</th>
<th>LC50 (mg/l)</th>
<th>Exposure time (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity to fish</td>
<td>Oncorhynchus mykiss (rainbow trout)</td>
<td>3.2</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Lepomis macrochirus (Bluegill sunfish)</td>
<td>9.6</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Ictalurus punctatus (channel catfish)</td>
<td>24</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Cyprinus carpio (Carp)</td>
<td>42</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Cyprinodon variegatus (sheepshead minnow)</td>
<td>15</td>
<td>96</td>
</tr>
<tr>
<td>Toxicity to daphnia and other aquatic invertebrates</td>
<td>Americamysis</td>
<td>0.022</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Daphnia magna (Water flea)</td>
<td>0.34</td>
<td>48</td>
</tr>
<tr>
<td>Toxicity to algae/aquatic plants</td>
<td>Pseudokirchneriella subcapitata (green algae)</td>
<td>100</td>
<td>72</td>
</tr>
</tbody>
</table>

---

**SDS Number:** 1212762-00014
**Date of last issue:** 26.04.2021
**Date of first issue:** 10.01.2017
M-Factor (Acute aquatic toxicity) : 10,000

Toxicity to microorganisms : EC50 : > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity) : NOEC: 0.52 µg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.03 µg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)

Toxicity to fish (Chronic toxicity) : NOEC: 0.0035 µg/l
Exposure time: 28 d
Species: Mysisidopsis bahia (opossum shrimp)

M-Factor (Chronic aquatic toxicity) : 10,000

(dl)-a-Tocopheryl acetate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 927 mg/l
Exposure time: 30 min
Method: ISO 8192

Toxicity to fish (Chronic toxicity) : NOEC: 100 mg/l
Exposure time: 28 d
Species: Oncorhynchus mykiss (rainbow trout)
12.2 Persistence and degradability

**Components:**

**N-Methyl-2-pyrrolidone:**
Biodegradability: Result: Readily biodegradable. Biodegradation: 73 % Exposure time: 28 d Method: OECD Test Guideline 301C

**Ivermectin:**
Biodegradability: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
Stability in water: Hydrolysis: 50 % (< 12 h)

**(dl)-a-Tocopheryl acetate:**

12.3 Bioaccumulative potential

**Components:**

**N-Methyl-2-pyrrolidone:**
Partition coefficient: n-octanol/water: log Pow: -0.46 Method: OECD Test Guideline 107

**Ivermectin:**
Bioaccumulation: Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water: log Pow: 3.22

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
Bioaccumulation: Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water: log Pow: 4

12.4 Mobility in soil

**Components:**

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
Distribution among environmental compartments: log Koc: > 3.6
12.5 Results of PBT and vPvB assessment

**Product:**
Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product** : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging** : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

**ADN** : UN 3082
**ADR** : UN 3082
**RID** : UN 3082
**IMDG** : UN 3082
**IATA** : UN 3082

14.2 UN proper shipping name

**ADN** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

**ADR** : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
## Ivermectin / Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5</td>
<td>27.08.2021</td>
<td>1212762-00014</td>
<td>26.04.2021</td>
<td>10.01.2017</td>
</tr>
</tbody>
</table>

(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

**RID**

: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.

((abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

**IMDG**

: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.

((abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

**IATA**

: Environmentally hazardous substance, liquid, n.o.s.

((abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

### 14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th>ADN</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>9</td>
</tr>
<tr>
<td>RID</td>
<td>9</td>
</tr>
<tr>
<td>IMDG</td>
<td>9</td>
</tr>
<tr>
<td>IATA</td>
<td>9</td>
</tr>
</tbody>
</table>

### 14.4 Packing group

**ADN**

Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

**ADR**

Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9  
Tunnel restriction code : (-)

**RID**

Packing group : III  
Classification Code : M6  
Hazard Identification Number : 90  
Labels : 9

**IMDG**

Packing group : III  
Labels : 9  
EmS Code : F-A, S-F

**IATA (Cargo)**

Packing instruction (cargo aircraft) : 964  
Packing instruction (LQ) : Y964  
Packing group : III  
Labels : Miscellaneous
Ivermectin / Abamectin Liquid Formulation

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 3 N-Methyl-2-pyrrolidone (Number on list 72, 71, 30)

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation : Not applicable
(Annex XIV)

<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H300: Fatal if swallowed.
H311: Toxic in contact with skin.
H315: Causes skin irritation.
H319: Causes serious eye irritation.
H330: Fatal if inhaled.
H335: May cause respiratory irritation.
H360D: May damage the unborn child.
H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child.
H370: Causes damage to organs if swallowed.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
Aquatic Chronic: Long-term (chronic) aquatic hazard
Eye Irrit.: Eye irritation
Repr.: Reproductive toxicity
Skin Irrit.: Skin irritation
STOT RE: Specific target organ toxicity - repeated exposure
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>SDS Number:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5</td>
<td>1212762-00014</td>
<td>10.01.2017</td>
</tr>
</tbody>
</table>

STOT SE 2009/161/EU : Specific target organ toxicity - single exposure

IE OEL : Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1

2009/161/EU / TWA : Limit Value - eight hours

2009/161/EU / STEL : Short term exposure limit

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

IE OEL / OELV - 15 min (STEL) : Occupational exposure limit value (15-minute reference period)

Further information


Classification of the mixture: Acute Tox. 4 H302

Classification procedure: Calculation method

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IEC - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - Quantitative Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative
Acute Tox. 4  H332  Calculation method
Skin Irrit. 2  H315  Calculation method
Eye Irrit. 2  H319  Calculation method
Repr. 1B  H360D  Calculation method
STOT SE 2  H371  Calculation method
STOT SE 3  H335  Calculation method
STOT RE 2  H373  Calculation method
Aquatic Acute 1  H400  Calculation method
Aquatic Chronic 1  H410  Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN